High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

Publikation

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

Wissenschaftlicher Artikel/Review - 20.10.2010

Thiel Eckhard, Birnbaum Tobias, Fischer Lars, Jahnke Kristoph, Herrlinger Ulrich, Plasswilm Ludwig, Nägele Thomas, Pietsch Torsten, Bamberg Michael, Leithäuser Malte, Mergenthaler Hans-Günther, Hundsberger Thomas, Korfel Agnieszka, Martus Peter, Kanz Lothar, Griesinger Frank, Rauch Michael, Röth Alexander, Hertenstein Bernd, von Toll Theda, Weller Michael

Zitation

Thiel E, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Leithäuser M, Mergenthaler H, Hundsberger T, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11:1036-47.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Lancet Oncol 2010; 11

Veröffentlichungsdatum

20.10.2010

eISSN (Online)

1474-5488

Seiten

1036-47

Kurzbeschreibung/Zielsetzung

High-dose methotrexate is the standard of care for patients with newly diagnosed primary CNS lymphoma. The role of whole brain radiotherapy is controversial because delayed neurotoxicity limits its acceptance as a standard of care. We aimed to investigate whether first-line chemotherapy based on high-dose methotrexate was non-inferior to the same chemotherapy regimen followed by whole brain radiotherapy for overall survival.